Bevyxxa is owned by Portola Pharms Inc.
Bevyxxa contains Betrixaban.
Bevyxxa has a total of 5 drug patents out of which 0 drug patents have expired.
Bevyxxa was authorised for market use on 23 June, 2017.
Bevyxxa is available in capsule;oral dosage forms.
Bevyxxa can be used as prophylaxis of deep vein thrombosis (dvt); prophylaxis of venous thrombosis, prophylaxis of pulmonary embolism, inhibiting coagulation.
Drug patent challenges can be filed against Bevyxxa from June, 2021.
The generics of Bevyxxa are possible to be released after 29 March, 2031.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7598276||PORTOLA PHARMS INC||Pharmaceutical salts and polymorphs of a factor Xa inhibitor|| |
(3 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9555023||PORTOLA PHARMS INC||Pharmaceutical salts and polymorphs of a factor Xa inhibitor|| |
(3 years from now)
|US8557852||PORTOLA PHARMS INC||Methods of using crystalline forms of a salt of a factor Xa inhibitor|| |
(5 years from now)
|US8987463||PORTOLA PHARMS INC||Methods of synthesizing factor Xa inhibitors|| |
(7 years from now)
|US8404724||PORTOLA PHARMS INC||Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor|| |
(8 years from now)
|New Chemical Entity Exclusivity (NCE)||Jun 23, 2022|
NCE-1 date: June, 2021
Market Authorisation Date: 23 June, 2017
Treatment: Prophylaxis of pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); Prophylaxis of venous thrombosis; Inhibiting coagulation
Korea, Republic of
Taiwan, Province of China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic